Pharmacist

Contract Year (CY) 2026 Medicare Part D Opioid Safety Edits – Submission Instructions, Recommendations, and Reminders

Medicare Part D sponsors must have concurrent drug utilization review (DUR) systems, policies, and procedures designed to ensure that a review of the prescribed drug therapy is performed before each prescription is dispensed to an enrollee in a sponsor’s Part D plan, typically at the POS or point of distribution as described in 42 CFR § 423.153(c)(2).
Medicare
AMCP Nexus Sign

Why You Should Attend Nexus 2025

Each fall, thousands of managed care professionals gather for AMCP Nexus, a dynamic meeting you'll connect with the people, ideas, and innovations shaping the future of pharmacy and health care. Nexus 2025 is shaping up to be our most engaging and insightful gathering yet with new features, big names, and an even greater focus on connection, wellness, and professional growth.
AMCP Membership
Pharmacists in Lab

AMCP Comment Letter on Medicare Drug Price Negotiation Program Draft Guidance

As CMS explores strategies to increase the adoption of digital health tools, AMCP urges CMS to support broader coverage of prescription digital therapeutics (PDTs) under Medicare and Medicaid. PDTs represent an emerging class of software-based treatments that deliver clinically validated therapeutic benefits, either independently or in combination with other interventions. These products can play a transformative role in improving access, especially for patients with behavioral health conditions or chronic diseases.
Quality of Care, Legislation & Regulation, Coverage Parity, Drug Utilization Review (DUR)